Bowel cancer “melted away” after immunotherapy, then stayed away
2 weeks ago
A short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer. In the NEOPRISM-CRC trial, 32 patients with a specific genetic form of bowel cancer received pembrolizumab for up to nine weeks before surgery instead of the usual post-surgery chemotherapy. After nearly three years of follow-up, none of the patients had ex...
phone_android📱 Use Epelcon on Your PhoneFaster. Always with you. Install the new Epelcon Mobile App v3.1.0 and access all 19 modules from your Android phone — Wallet, Jobs, Property, Diet Plans, Courses, Blog & more.Get the App
Advertise With Us!
Promote your brand, products or services across our homepage, shop, blog, email newsletters & social media channels.
This website uses cookies to enhance your browsing experience, serve personalized content, and analyze our traffic. By clicking “Accept”, you consent to our use of cookies.